Brensocatib

Chemical compound From Wikipedia, the free encyclopedia

Brensocatib, sold under the brand name Brinsupri, is a medication used for the treatment of bronchiectasis.[1] It is a dipeptidyl peptidase 1 (DPP1) inhibitor.[1][4] It is taken by mouth.[1]

Trade namesBrinsupri
Other namesAZD7986; INS1007
AHFS/Drugs.comMonograph
MedlinePlusa625099
Quick facts Clinical data, Trade names ...
Brensocatib
Clinical data
Trade namesBrinsupri
Other namesAZD7986; INS1007
AHFS/Drugs.comMonograph
MedlinePlusa625099
License data
Routes of
administration		By mouth
Drug classDipeptidyl peptidase 1 inhibitor
ATC code
  • None
Legal status
Legal status
Identifiers
  • (2S)-N-[(1S)-1-cyano-2-[4-(3-methyl-2-oxo-1,3-benzoxazol-5-yl)phenyl]ethyl]-1,4-oxazepane-2-carboxamide
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC23H24N4O4
Molar mass420.469 g·mol−1
3D model (JSmol)
  • CN1C2=C(C=CC(=C2)C3=CC=C(C=C3)C[C@@H](C#N)NC(=O)[C@@H]4CNCCCO4)OC1=O
  • InChI=1S/C23H24N4O4/c1-27-19-12-17(7-8-20(19)31-23(27)29)16-5-3-15(4-6-16)11-18(13-24)26-22(28)21-14-25-9-2-10-30-21/h3-8,12,18,21,25H,2,9-11,14H2,1H3,(H,26,28)/t18-,21-/m0/s1
  • Key:AEXFXNFMSAAELR-RXVVDRJESA-N
Close

Brensocatib was approved for medical use in the United States in August 2025,[1][5] and in the European Union in November 2025.[2][3]

Medical uses

Brensocatib is indicated for the treatment of non-cystic fibrosis bronchiectasis in people aged twelve years of age and older.[1]

History

Bresocatib was discovered as a second generation DPP1 inhibitor, by scientists at AstraZeneca, eliminating aorta binding liabilities found with earlier compound series.[6] A phase III clinical trial, known as the ASPEN trial, was conducted to evaluate the safety and efficacy of brensocatib in patients with non-cystic fibrosis bronchiectasis.[7]

Society and culture

Brensocatib was approved for medical use in the United States in August 2025.[8]

In October 2025, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Brinsupri, intended for the treatment of non-cystic fibrosis bronchiectasis in people aged twelve years of age and older.[2][9] The applicant for Brinsupri is Insmed Netherlands B.V.[10] Brensocatib was authorized for medical use in the European Union in November 2025.[2][3]

Names

Brensocatib is the international nonproprietary name.[11]

Brensocatib is sold under the brand name Brinsupri.[1]

References

External links

Related Articles

Wikiwand AI